ASG-5ME: Phase I started

Seattle Genetics began an open-label, dose-escalation, U.S. Phase I trial to evaluate 0.3-1.5 mg/kg IV ASG-5ME in about 50 patients. Seattle Genetics and Astellas' Agensys Inc. subsidiary partnered t...